Want to see ASMB full AI Analyst Report?
ASMB Stock Chart & Stats
$35.33
$0.60(2.35%)
At close: 4:00 PM EDT
$35.33
$0.60(2.35%)
Day’s Range― - ―
52-Week Range$20.23 - $39.71
Previous CloseN/A
Volume1.34K
Average Volume (3M)263.85K
Market Cap
$620.18M
Enterprise Value$200.09
Total Cash (Recent Filing)$320.36M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)54.2
Beta1.39
Next Earnings
Nov 11, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding20,360,596
10 Day Avg. Volume258,076
30 Day Avg. Volume263,849
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$49.50Price Target Upside40.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$52.01M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Low LeverageVery low leverage and a substantially expanded equity base provide financial flexibility for a clinical-stage company. Limited debt-related pressure preserves capacity to fund research, absorb development setbacks, and pursue strategic opportunities without heavy mandatory repayment burdens.
Material Revenue Growth With Strong Gross MarginThe sharp increase in revenue and high reported gross margin indicate that collaboration and licensing activities can generate meaningful economic value. Although revenue may be milestone-driven, this scale improves funding capacity and supports continued investment in the pipeline.
Expanded Partnered Antiviral Opportunity With GileadThe Gilead collaboration gives Assembly exposure to a partnered antiviral program while retaining potential U.S. profit participation and overseas royalties. Gilead remains responsible for development and commercialization, which can extend the pipeline’s opportunity without requiring Assembly to lead every activity.
Bears Say
Persistent Operating And Free Cash Flow BurnNegative operating and free cash flow show that the business is not yet self-funding and continues to consume cash supporting operations and development. Sustained burn can require additional financing or partnership proceeds, reducing financial resilience if expected inflows are delayed.
Operating Profitability Remains Negative And Results Are VolatileNear-breakeven net income has not yet translated into positive operating profitability, leaving earnings dependent on variable revenue and collaboration activity. Continued volatility makes forecasting more difficult and weakens confidence that current improvement represents a durable recurring earnings base.
Equity Financing Creates Dilution RiskFunding clinical development through equity increases the company’s cash resources but expands the share base, diluting existing holders. If development programs require repeated capital raises before becoming self-funding, dilution can remain a structural cost of pursuing the pipeline.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $20.23 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $620.18M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 59 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.524.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.66.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 20,360,596 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 10.017%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (40.11% Upside)
$49.50 (40.11% Upside)
Blogger Sentiment
Bullish
ASMB Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 376.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $674.3 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.9%
Last 30 Days ▲ 44.9%
Last 30 Days ▲ 44.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
309.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$49.50
▲(40.11% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
26.40% Insiders
3.69% Mutual Funds
63.30% Other Institutional Investors
1.30% Public Companies and
Individual Investors